Windtree Therapeutics, Inc. (WINT), a biotechnology company, announced promising topline results from its Phase 2b SEISMiC Extension Study on Wednesday. The study demonstrated that istaroxime significantly increased systolic blood pressure over a six-hour period, a critical clinical objective for treating patients experiencing early cardiogenic shock due to heart failure.
The SEISMiC Extension Study is being carried out across the United States, Europe, and Latin America. The focus of the study is to evaluate the impact of istaroxime on blood pressure, cardiac function, and other key parameters over a 96-hour period, with a final follow-up at 30 days.
These findings build upon the positive data previously reported from the Phase 2 SEISMiC trial. The Extension Study aims to improve low blood pressure and cardiac function in early cardiogenic shock patients and to explore additional potential benefits. Moreover, it provides valuable insights for dose optimization and a better understanding of istaroxime's mechanism of action, including the possible advantages of SERCA2a activation.
